High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Radiology

• Publication date

  2010-06-23

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.1007/s00330-010-1805-8PMID 20567832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium.

  2011cited by this paper
• Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas

  2011cited by this paper
• Dynamic magnetic resonance angiography of the arteries of the hand. A comparison between an extracellular and an intravascular contrast agent

  2009cited by this paper
• Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 tesla

  2009cited by this paper
• Brain Tumor Enhancement in Magnetic Resonance Imaging at 3 Tesla: Intraindividual Comparison of Two High Relaxivity Macromolecular Contrast Media With a Standard Extracellular Gd-Chelate in a Rat Brain Tumor Model

  2009cited by this paper
• Role of diffusion- and perfusion-weighted MR imaging for brain tumour characterisation

  2009cited by this paper
• Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

  2009cited by this paper
• Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.

  2009cited by this paper
• Multicenter, double‐blind, randomized, intra‐individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla

  2009cited by this paper
• Intra-individual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Angiography of the Supraaortic Vessels at 3 Tesla

  2008cited by this paper
• Perfusion Magnetic Resonance Imaging in Psychiatry

  2008cited by this paper
• Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.

  2008cited by this paper
• Contrast-Enhanced MR Imaging of Brain Lesions: A Large-Scale Intraindividual Crossover Comparison of Gadobenate Dimeglumine versus Gadodiamide

  2008influential reference
• Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial

  2008cited by this paper
• Gadofosveset-enhanced magnetic resonance angiography

  2008influential reference
• A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents

  2008cited by this paper
• Magnetic resonance angiography of the head and neck vessels.

  2007cited by this paper
• MRI of tumor angiogenesis

  2007cited by this paper
• Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.

  2007influential reference
• MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

  2007cited by this paper
• Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

  2007influential reference
• Magnetic resonance angiography with blood-pool contrast agents: future applications.

  2007cited by this paper
• Nephrogenic systemic fibrosis: risk factors and incidence estimation.

  2007cited by this paper
• Recent advances in contrast-enhanced magnetic resonance angiography.

  2007cited by this paper
• First-Pass Whole-Body Magnetic Resonance Angiography (MRA) Using the Blood-Pool Contrast Medium Gadofosveset Trisodium: Comparison to Gadopentetate Dimeglumine

  2007cited by this paper
• Improving lesion detection and visualization: implications for neurosurgical planning and follow-up

  2007cited by this paper
• Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.

  2006influential reference
• The advantage of high relaxivity contrast agents in brain perfusion

  2006cited by this paper
• Contrast-Enhanced Magnetic Resonance Imaging of Central Nervous System Tumors: Agents, Mechanisms, and Applications

  2006cited by this paper
• Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.

  2006cited by this paper
• Multiple sclerosis: the role of MR imaging.

  2006cited by this paper
• Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors

  2006cited by this paper
• Intraindividual Comparison of Gadobenate Dimeglumine and Gadobutrol for Cerebral Magnetic Resonance Perfusion Imaging at 1.5 T

  2006influential reference
• Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast Agents

  2006cited by this paper
• Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla

  2006influential reference
• Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths

  2005cited by this paper
• MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.

  2005cited by this paper
• Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time‐resolved contrast‐enhanced three‐dimensional magnetic resonance angiography of the upper torso

  2005cited by this paper
• Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T

  2005cited by this paper
• Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.

  2005cited by this paper
• Gadobenate dimeglumine (MultiHance) in MR imaging of the CNS: studies to assess the benefits of a high relaxivity contrast agent.

  2005cited by this paper
• Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study.

  2005cited by this paper
• Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

  2004influential reference
• MR angiography with MultiHance for imaging the supra-aortic vessels

  2004cited by this paper
• Contrast-Enhanced Three-Dimensional Pulmonary Perfusion Magnetic Resonance Imaging: Intraindividual Comparison of 1.0 M Gadobutrol and 0.5 M Gd-DTPA at Three Dose Levels

  2004cited by this paper
• A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours

  2004cited by this paper
• Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.

  2003cited by this paper
• Clinical experience with multihance in CNS imaging

  2003cited by this paper
• Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography.

  2003cited by this paper
• Intraindividueller Vergleich dreier Kontrastmittel (Gd-DTPA, Gd-BOPTA und Gd-BT-DO3A) mit der multiphasischen MR-Angiographie

  2003cited by this paper
• Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol.

  2003influential reference
• [Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A].

  2003cited by this paper
• Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance Angiography

  2003cited by this paper
• Assessment of Gadobenate Dimeglumine for Magnetic Resonance Angiography: Phase I Studies

  2002cited by this paper
• Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol

  2002cited by this paper
• Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

  2002cited by this paper
• Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine

  2002cited by this paper
• 0.5 M Gd chelate (Magnevist®) versus 1.0 M Gd chelate (Gadovist®): Dose‐independent effect on image quality of pelvic three‐dimensional MR‐angiography

  2001cited by this paper
• Detection of Intracranial Metastases: A Multicenter, Intrapatient Comparison of Gadobenate Dimeglumine-Enhanced MRI with Routinely Used Contrast Agents at Equal Dosage

  2001cited by this paper
• Gadobenate dimeglumine‐enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation

  2001cited by this paper
• Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence.

  2000cited by this paper
• New techniques in MR imaging of brain tumors.

  2000cited by this paper
• Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.

  1999cited by this paper
• Clinical applications of intracranial perfusion MR imaging.

  1999cited by this paper
• Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium.

  1999influential reference
• Comparison of single- and triple-dose contrast material in the MR screening of brain metastases.

  1998cited by this paper
• Magnetic resonance angiography with gadomer-17. An animal study original investigation.

  1998cited by this paper
• Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.

  1997cited by this paper
• Signal‐to‐noise analysis of cerebral blood volume maps from dynamic NMR imaging studies

  1997cited by this paper
• High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results

  1996cited by this paper
• Acute human stroke studied by whole brain echo planar diffusion‐weighted magnetic resonance imaging

  1995cited by this paper
• Mr contrast due to intravascular magnetic susceptibility perturbations

  1995cited by this paper
• Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.

  1994cited by this paper
• Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients.

  1993cited by this paper
• Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases.

  1992cited by this paper
• High‐dose gadoteridol in MR imaging of intracranial neoplasms

  1992cited by this paper
• MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

  1991cited by this paper
• Perfusion imaging with NMR contrast agents

  1990cited by this paper
• Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats.

  1990cited by this paper
• Perfusion imaging by nuclear magnetic resonance.

  1989cited by this paper
• Dynamic imaging with lanthanide chelates in normal brain: Contrast due to magnetic susceptibility effects

  1988cited by this paper
• Value of 1

  1982cited by this paper

• Multifunctional nanoprobe for near-infrared and magnetic resonance dual-modal amyloid-β imaging and oxidative stress monitoring in early stage of Alzheimer's disease

  2025cites this paper
• GCN5-targeted dual-modal probe across the blood-brain barrier for borders display in invasive glioblastoma

  2025cites this paper
• Recomendaciones para el uso de medios de contraste basados en gadolinio en estudios con resonancia magnética del sistema nervioso central

  2025cites this paper
• Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas

  2023cites this paper
• Effect of gadopentetate dimeglumine on bone growth in zebrafish caudal fins.

  2022cites this paper
• Rare-earth based materials: an effective toolbox for brain imaging, therapy, monitoring and neuromodulation

  2022cites this paper
• A narrative review of adjuvant therapy for glioma: hyperbaric oxygen therapy

  2021cites this paper
• Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma

  2021cites this paper
• Signal Intensity Changes in the Dentate Nucleus and Globus Pallidus of Multiple Sclerosis Patients Undergoing Multiple Brain Magnetic Resonance Imaging with Gadolinium-Based Contrast Agents

  2021cites this paper
• Reduction-active Fe3O4-loaded micelles with aggregation- enhanced MRI contrast for differential diagnosis of Neroglioma.

  2020cites this paper
• Technique and protocols for cardiothoracic time-resolved contrast-enhanced magnetic resonance angiography sequences: a systematic review.

  2020cites this paper
• Brain DSC MR Perfusion in Children: A Clinical Feasibility Study Using Different Technical Standards of Contrast Administration

  2019cites this paper
• T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter

  2018cites this paper
• Peripheral Biomarkers of Inflammation Following Blast Exposure in a Clinical Population

  2018cites this paper
• Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.

  2018cites this paper
• An interleaved sequence for simultaneous magnetic resonance angiography (MRA), susceptibility weighted imaging (SWI) and quantitative susceptibility mapping (QSM).

  2018cites this paper
• Targeting Upconversion Nanoprobes for Magnetic Resonance Imaging of Early Colon Cancer

  2017cites this paper
• Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.

  2017cites this paper
• From Tissue Perfusion to Oxygenation: Characterizing Glioma Heterogeneity with Dynamic Susceptibility Contrast Enhanced Magnetic Resonance Imaging

  2017cites this paper
• Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias

  2017cites this paper
• Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography

  2017cites this paper
• Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents—current status

  2016cites this paper
• Glioma vessel abnormality quantification using time-of-flight MR angiography

  2016cites this paper
• Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol

  2016cites this paper
• In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents

  2016cites this paper
• Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast‐enhanced MR imaging of the central nervous system

  2015influential citation
• Glioma-targeting micelles for optical/magnetic resonance dual-mode imaging

  2015cites this paper
• Basic MR relaxation mechanisms and contrast agent design

  2015cites this paper
• Chronic cerebral hypoperfusion induces vascular plasticity and hemodynamics but also neuronal degeneration and cognitive impairment

  2015cites this paper
• The utility of gadoteric acid in contrast-enhanced MRI: a review

  2015influential citation
• Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.

  2015cites this paper
• A review of responsive MRI contrast agents: 2005-2014.

  2015cites this paper
• In vivo MR imaging of intercellular adhesion molecule-1 expression in an animal model of multiple sclerosis.

  2015cites this paper
• Contrast Agents in Radiology

  2014cites this paper
• B25716/1: a novel albumin-binding Gd-AAZTA MRI contrast agent with improved properties in tumor imaging

  2014cites this paper
• Dynamic gadobutrol‐enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model

  2014cites this paper
• Dual-targeting upconversion nanoprobes across the blood-brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma.

  2014cites this paper
• Imaging of cerebrovascular pathology in animal models of Alzheimer's disease

  2014cites this paper
• Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.

  2014influential citation
• Comparison between 0 . 1 mmol / kg of gadoterate meglumine and 0 . 075 of gadobenate dimeglumine in brain MRI

  2014cites this paper
• An Introduction to Brain Tumor Imaging

  2014cites this paper
• Dynamic contrast-enhanced magnetic resonance angiography of Gd-TTDA-BOM compared with Gd-DTPA in normal rat at 3T

  2014cites this paper
• Intraindividual and interindividual comparison etween 0 . 075

  2014influential citation
• Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?

  2013cites this paper
• Arterial input function in perfusion MRI: a comprehensive review.

  2013cites this paper
• Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma

  2013cites this paper
• Magnetic resonance microscopy.

  2013cites this paper
• Longitudinal Assessment of Amyloid Pathology in Transgenic ArcAβ Mice Using Multi-Parametric Magnetic Resonance Imaging

  2013cites this paper
• Overview on the efficacy and safety of gadobutrol: an MRI contrast agent for the CNS, body and vessels

  2012cites this paper
• Multiple Sclerosis Role of Contrast-enhanced Magnetic Resonance Imaging in Multiple Sclerosis

  2012cites this paper
• MR Angiography and Development: Review of Clinical Applications

  2012influential citation
• Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier.

  2012cites this paper
• Clinical use of gadobutrol for contrast-enhanced magnetic resonance imaging of neurological diseases

  2012cites this paper
• Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice.

  2012cites this paper
• Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.

  2012cites this paper
• Efficacy and Safety of Gadobutrol (1.0 M) versus Gadopentetate Dimeglumine (0.5 M) for Enhanced MRI of CNS Lesions: A Phase III, Multicenter, Single-Blind, Randomized Study in Chinese Patients

  2012cites this paper
• Modern Trends in Imaging VII: Magnetic Resonance Microscopy

  2011cites this paper
• Brain Tumour Imaging

  2011influential citation